Roche NimbleGen

About Roche NimbleGen

Roche NimbleGen operates as a key entity within Roche's life sciences and diagnostics portfolio, specializing in DNA sequencing solutions. The company's origins trace back to NimbleGen Systems, Inc., founded in 1999 as a spin-off from the University of Wisconsin-Madison by a team including Professor Franco Cerrina. This foundation was built upon light-directed chemical synthesis technology, initially developed for creating high-density DNA microarrays. A pivotal moment in the company's trajectory occurred in 2007 when Roche acquired NimbleGen Systems for $272.5 million, integrating it into its Roche Applied Science division. This acquisition was a strategic move by Roche to bolster its capabilities in genomics and DNA sequencing, particularly in the research market.

The core of Roche NimbleGen's business revolves around providing tools for genetic research, with a primary focus on target enrichment technologies for next-generation sequencing (NGS). Its main clients are academic research institutions, pharmaceutical companies, and clinical research organizations that require detailed analysis of specific regions of the genome. The business model is centered on the sale of these specialized products, primarily SeqCap EZ and SeqCap RNA probe pools, which allow researchers to isolate specific DNA or RNA sequences from a complex sample before sequencing. This process significantly improves the efficiency and reduces the cost of sequencing by concentrating on genomic areas of interest.

The company's key offering, the Sequence Capture technology, enables researchers to design experiments that are both high-throughput and economical. By enriching for specific genetic targets, scientists can gain a clearer understanding of genomic structure and function, which is crucial for studying the impact of genes on biological processes and diseases. This capability is instrumental in fields like oncology, human genetics, and agricultural genomics. The Madison, Wisconsin site continues to be a hub for research, development, and manufacturing of these essential target enrichment probe pools, contributing to Roche's broader strategy in sequencing solutions for life science research.